---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-084159"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:43:21.669325+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics receives FDA Rare Pediatric Drug Designation for VCN-01 in retinoblastoma

## Summary
- FDA grants Rare Pediatric Drug Designation for VCN-01, a stroma-degrading oncolytic adenovirus, to treat retinoblastoma.
- Prior orphan drug designation for same indication; RPDD may provide a Priority Review Voucher upon BLA approval.
- Holders of Series C Convertible Preferred Stock converted 135,431 shares into 888,072 common shares at $1.22 per share.
- Positive Phase 1 results from investigator-sponsored trial of intravitreal VCN-01 in pediatric refractory retinoblastoma inform clinical pathway.

## SEC filing metadata
- accession: 0001104659-24-084159
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465924084159/0001104659-24-084159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465924084159/tm2420486d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-084159
- JSON: https://secwatch.observer/filing/0001104659-24-084159.json
- Plain text: https://secwatch.observer/filing/0001104659-24-084159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.